Viatris To Bring In Plenty Of Brand Knowledge With New CEO Smith
Board Member Smith To Jump Quickly Into CEO Seat, Replacing Goettler
Only three months after joining Viatris’ board of directors, Scott Smith, famed for spearheading Celgene’s successful and lucrative Inflammation and Immunology division, has been announced as the company’s new CEO, beginning 1 April.
You may also be interested in...
Stock Watch: The Transatlantic Asymmetries Of Generic Drugs
Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?
Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers
In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation from parent company Novartis, as well as outlining its unique position as a pure generics and biosimilars company among an evolving peer group of off-patent industry leaders.
Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.